Remove Bacteria Remove FDA Approval Remove Sales
article thumbnail

Journey Medical’s Emrosi Wins FDA Approval for Rosacea, Could Rival Galderma’s Oracea

XTalks

Research suggests that certain bacteria, particularly those associated with Demodex mites (tiny mites that naturally live on human skin) like Bacillus oleronius , could contribute to rosacea in some individuals. Other studies suggest that Helicobacter pylori bacteria infections may also cause rosacea.

article thumbnail

Merck’s Next-Generation Pneumonia Vaccine Gets FDA Approval

XTalks

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis’ Fabhalta Gets FDA Approval for Rare Complement Blood Disorder

XTalks

After receiving US Food and Drug Administration (FDA) approval for Fabhalta (iptacopan) last week for the treatment of the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH), Novartis presented trial data yesterday showing the drug’s promise in another indication.

article thumbnail

Merck’s Capvaxive Wins FDA Approval as First Pneumonia Vaccine Designed for Adults

XTalks

In 2023, Vaxneuvance, which was approved in 2021, netted $665 million in sales. Last year, sales of Pfizer’s pneumococcal vaccines reached $6.4 However, Vaxneuvance has contributed to slowing down Prevnar 20’s sales growth from 20 percent in 2022 to two percent last year.

article thumbnail

Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine

Pharmaceutical Technology

The company says that these four serotypes represent roughly 10–15% of bacteria causing pneumococcal disease in adults. While the first pneumococcal polysaccharide vaccine was approved in the US in 1977, the first conjugate shot Prevnar was greenlighted only in 2000. VAX-24 has forecasted sales of $21 million in the same year.

article thumbnail

Eli Lilly Reaches Settlement with Totality MediSpa Over Sale of Compounded Mounjaro and Zepbound

XTalks

The settlement requires Totality to take several specific corrective actions, which include refraining from making any statements that suggest the spa’s products are genuine, FDA-approved Lilly products, and stopping the use of Eli Lilly branding in promoting any of the products.

Sales 52
article thumbnail

Nestlé to Market Seres’ Oral Microbiome Drug for C. Difficile

XTalks

CDIs usually develop after treatments with antibiotics as they can kill off healthy bacteria in the gut in the process of targeting the pathogenic bacteria. As part of the deal with Nestlé, Seres will receive license payments of $175 million up front with an additional $125 million upon FDA approval of the drug.

Marketing 105